Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure.

ABSTRACT:

Background and objectives

Recent studies have shown that sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF)-associated hospitalization and mortality in patients with diabetes. However, it is not clear whether SGLT2 inhibitors have a cardiovascular benefit in patients without diabetes. We aimed to determine whether empagliflozin (EMPA), an SGLT2 inhibitor, has a protective role in HF without diabetes.

Methods

Cardiomyopathy was induced in C57BL/6J mice using intraperitoneal injection of doxorubicin (Dox). Mice with HF were fed a normal chow diet (NCD) or an NCD containing 0.03% EMPA. Then we analyzed their phenotypes and performed in vitro experiments to reveal underlying mechanisms of the EMPA's effects.

Results

Mice fed NCD with

SUBMITTER: Oh CM 

PROVIDER: S-EPMC6875592 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature